Bisphosphonate-induced orbital inflammation: a case series and review
Date
2015
Authors
Pirbhai, A.
Rajak, S.
Goold, L.
Cunneen, T.
Wilcsek, G.
Martin, P.
Leibovitch, I.
Selva, D.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Orbit, 2015; 34(6):331-335
Statement of Responsibility
Adnan Pirbhai, Saul N. Rajak, Lucy A. Goold, Thomas S. Cunneen, Geoff Wilcsek, Peter Martin, Igal Leibovitch, and Dinesh Selva
Conference Name
Abstract
Introduction: To present a series of patients with bisphosphonate induced orbital inflammation, and to review the clinical presentation, radiological features, treatment options and outcomes. Methods: We present a multicentre, retrospective case series review of patients with a clinico-radiological diagnosis of bisphosphonate induced orbital inflammation and review all the reported cases of this complication in the literature. Results: Four new patients with bisphosphonate induced orbital inflammation were added to the 25 cases in the literature. Intravenous zoledronate was the commonest precipitant (22/29, 75.9%) and inflammation occurred 1–28 (mean 3) days post-infusion. Orbital imaging identified orbital inflammation in 22/29 cases and extra- ocular muscle enlargement in 8/29. Five patients presented with reduced vision of which one - with anterior ischaemic optic neuropathy - did not resolve. The vision resolved in all except one patient, with most requiring steroid treatment. Conclusions: Bisphosphonates have a pro-inflammatory effect, which can precipitate orbital inflammation. This rare, but potentially serious complication of bisphosphonate treatment should be considered by clinicians using bisphosphonate treatment and by ophthalmologists seeing patients with orbital inflammatory disease.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
Crown Copyright